Related Experiment Videos
MIMA-9, a valuable antibody for screening for rare donors
E Tossas1, R Øyen, G R Halverson
1Immunohematology Laboratory, New York Blood Center, 310 East 67th Street, New York, NY 10021, USA.
Immunohematology
|September 18, 2004
Summary
Monoclonal antibody MIMA-9 enables simultaneous screening of red blood cells for multiple high-incidence antigen-negativities in Kell and Gerbich blood group systems. This method efficiently identifies rare blood types, aiding donor selection.
Area of Science:
- Transfusion Medicine
- Immunology
- Hematology
Background:
- Monoclonal antibodies (Mabs) offer a scalable solution for screening blood donors.
- Identifying antigen-negative donors is crucial for transfusion safety.
- Existing methods for identifying rare blood types can be resource-intensive.
Purpose of the Study:
- To evaluate the efficacy of MIMA-9 monoclonal antibody for simultaneous screening of red blood cells (RBCs) for high-incidence antigen-negativity.
- To assess the utility of MIMA-9 in identifying rare Kell and Gerbich blood group phenotypes.
- To demonstrate the cost-effectiveness and efficiency of MIMA-9 in donor screening.
Main Methods:
- Utilized MIMA-9, a murine IgG2a antibody, in MTS gel cards with anti-mouse IgG.
- Screened 1134 donors preselected for K- antigen status.
- Employed MIMA-9 for simultaneous detection of K+k-, Kp(a+b-), K0, McLeod, and Ge:-3 RBCs.
Main Results:
- Identified one Kp(a+b-) donor and one Ge:-2,-3,4 donor among 1134 K- donors.
- MIMA-9 successfully screened for multiple high-incidence antigens simultaneously.
- The reagent is also effective for typing RBCs with a positive direct antiglobulin test.
Conclusions:
- MIMA-9 is a valuable reagent for efficient and simultaneous screening of rare blood types.
- This monoclonal antibody conserves rare antisera and streamlines donor blood screening processes.
- MIMA-9 is available at no cost for donor screening laboratories, promoting wider adoption.